After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
(Adds details, results of subsidiary, and background)
July 30 (Reuters) - German healthcare group Fresenius raised its full-year revenue target on Tuesday, citing solid second-quarter performance of all units, even as results of its key dialysis business came in slightly below expectations.
The group said its second-quarter core operating profit (EBIT) fell by 5% to 1.12 billion euros ($1.25 billion) on an adjusted basis, while currency-adjusted revenue rose 6% to 8.8 billion euros, broadly in line with analysts' expectations in a Refinitiv poll.
The outlook is adjusted for the effects of an acquisition of the U.S. home dialysis firm NxStage in February, Fresenius said.
The company expects full-year revenue growth between 4% and 7% in constant currency, compared with previous range of 3%-6%.
The company's separately listed dialysis unit Fresenius Medical Care reported its adjusted second-quarter revenue at 4.28 billion euros, below 4.35 billion euros expected on average by analysts in a Refinitiv poll.
Fresenius Medical confirmed its full-year guidance and still expects adjusted sales to rise up to 7%, and adjusted net income change to be between -2% and 2% despite adjustments made as a precaution in the pilot program for value-based care in the United States.
($1 = 0.8980 euros) (Reporting by Zuzanna Szymanska and Bartosz Dabrowski in Gdynia, Editing by Tomasz Janowski and Sherry Jacob-Phillips)